Biotechnology company developing novel oncology therapeutics based on a deep understanding of the human immune response
Location: United States, California, Redwood City
Total raised: $222M
Investors 4
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | HCL Capita... | hcl-capita... |
| - | Mission Bi... | missionbio... |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 12.09.2018 | Series C | $125M | - |
| 20.08.2017 | Series B | $35M | - |
| 04.11.2015 | Series A | $56M | - |
| 25.09.2012 | - | $6M | - |
Mentions in press and media 12
| Date | Title | Description |
| 29.07.2021 | Atreca : Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors | Completed dose escalation portion of Phase 1b trial; ATRC-101 was well-tolerated with no dose-limiting toxicities observed Disease control associated with ATRC-101 target expression; preliminary biomarker data support the proposed mechanism... |
| 16.09.2018 | Atreca Raises $125M in Series C Funding | Atreca, Inc., a Redwood City, Calif.-based biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, closed a $125m Series C financing. The round was led by an existing invest... |
| 14.09.2018 | Term Sheet — Friday, September 14 | BORING IS THE NEW BLACK Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop BORING IS GOOD? I can’t stop thinking about this NYT story by Farhad Manjoo, in which he explores the notion that i... |
| 12.09.2018 | Atreca raises $125M in oversubscribed Series C funding round | The unnamed fund also co-led Atreca’s Series B financing round worth $35 million, which it completed in August 2017, alongside then-new investor Wellington. Atreca’s pipeline page lists three programs. ATRC-101’s mechanism of action involve... |
| 20.08.2017 | Wellington Management Leads $35M Series B for Atreca | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced the completion of its Series B round of financing wi... |
| 17.08.2017 | Term Sheet — Thursday, August 17 | CROWDFUNDING, 40 UNDER 40, FEES, DRY POWDER CROWDFUNDING: The JOBS Act, with its crowdfunding provision, was supposed to be kick off a revolution. Now anyone could invest in high-risk startup equity. It was supposed to disrupt the entire bu... |
| 17.08.2017 | Atreca Completes $35M Series B Financing | Atreca, Inc., a Redwood City, Calif.-based biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, completed a $35M Series B financing. The round was co-led by Wellington Ma... |
| 17.08.2017 | Atreca Raises $35M Series B Round | REDWOOD CITY, CA, Atreca has closed $35 million in Series B financing. >> Click here for more funding data on Atreca >> To export Atreca funding data to PDF and Excel, click here Atreca, a biotechnology company focused on... |
| 04.11.2015 | Atreca Completes $56M Series A Funding | Atreca, Inc., a Redwood City, CA-based biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, completed its $56m Series A funding. The round was led by a large U.S.-based, ... |
| 04.11.2015 | Daily funding roundup - November 4, 2015 | Atreca completed $56M funding; Zhihu raised $50M; The History Project launched with $2M funding The History Project, an Oakland, CA-based platform that allows users to take control of digital and physical assets and build them into shareabl... |
Show more